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Figure S1. AMBN induces apoptosis and sensitivity to doxorubicin in osteosarcoma cells, 
related to Figure 1. (A) Representative results of cell cycle distributions analyzed by PI 
staining and FACS in control and AMBN-stable 143B-Luc cells are shown. (B) The 
expression of FLAG-AMBN and cleaved caspase-3 in control and AMBN-stable 143B-Luc 
cells was examined. (C) After the treatment with DMSO and doxorubicin (0.5 µg/mL) for 
24 h in control and AMBN-stable 143B-Luc cells, cleaved caspase-3 expression was 
examined. 
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Figure S2. AMBN induces apoptosis and sensitivity to doxorubicin through the 
inactivation of Src-Stat3 pathway in osteosarcoma cells, related to Figure 1. (A) Control 
and AMBN-inducible 143B-Luc cells were cultured for 3 days with Cumate solution 
(300µg/mL). The cells were collected each day and the expression of FLAG-AMBN and 
cleaved caspase-3 was evaluated. (B) Control and AMBN-inducible 143B-Luc and U2-OS 
cells were cultured with Cumate solution, and cell growth was counted on days 0, 1, 2, and 
3 (N=3). (C) Control and AMBN-inducible 143B-Luc and U2-OS cells were cultured with 
Cumate for 3 days, and these cells were treated with DMSO and doxorubicin (0.5 µg/mL) 
at last 24 h. The expression of FLAG-AMBN and cleaved caspase-3 was examined.  (D) 
The expression of FLAG-AMBN, pY705-Stat3, total-Stat3 and cleaved caspase-3 was 
examined. (E) The expression of FLAG-AMBN, pY416-Src, total-Src and cleaved 
caspase-3 after attachment on the culture dish (0, 30, 60 minutes) was examined. 
Mean±SEM (B); ***, P＜0.001. 
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Figure S3. CD63 is expressed among human osteosarcoma cell lines and is needed for 
Stat3 inactivation induced by AMBN, related to Figure 1. (A) The expression of CD63 at 
the protein level in NOS-1, SaOS-2, U2-OS and 143-B Luc cells was examined. (B) 
shScramble and shCD63 were transfected into AMBN-inducible 143B-Luc cells. The 
expression of FLAG-AMBN, CD63, pY705-Stat3 and total-Src at the protein level in was 
examined. 
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Figure S4. AMBN suppresses cell migration in osteosarcoma cells, related to Figure 2. 
Control and AMBN-inducible 143B-Luc cells were cultured with Cumate for 3 days. Cell 
migration activity was examined by wound healing assay. Representative images at 5 h are 
shown (left panels) and wound areas were quantified (right graph) (N=3). Original 
magnification of the left panels: ×100. Mean±SEM; **, P＜0.01. 
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Figure S5. AMBN suppresses colony formation through the inactivation of Src-Stat3 
pathway in osteosarcoma cells, related to Figure 3. (A and B) 143B-Luc cells were 
pretreated with SU6656 or S3I-201 at indicated concentrations for 24 h. Colony formation 
in pretreated 143B-Luc cells was analyzed and representative colonies were shown.  
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Figure S6. Knockdown of AMBN promotes cell migration and colony formation through 
Src-Stat3 axis in osteosarcoma cells, related to Figure 3. shAMBN-2 NOS-1 cells were 
pretreated with SU6656 at indicated concentrations. (A and C) Cell migration activity of 
pretreated NOS-1 cells was examined. Representative images of wound areas at 5 h are 
shown. (B and D) Colony formation in pretreated shAMBN-2 NOS-1 cells was analyzed 
and representative colonies are shown. 
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Figure S7. Stable AMBN overexpression inhibits tumor growth and pulmonary metastases 
in vivo, related to Figure 4. (A) Bone erosion of primary tumors in empty and AMBN 
group are shown. (B) The pictures of primary tumors in control and AMBN-stable group 
are shown (upper panel). AMBN mRNA in the primary tumor was evaluated (lower panel). 
(C) The volume of primary tumors at indicated days was measured (N=10). (D) The 
primary tumors were weighed after the sacrifice (N=10). (E) The number of metastatic foci 
in lung was counted by HE staining (N=10). (F) Representative necrotic area (lower left 
area: necrosis, right upper area: viable tumor cells) of primary tumor in AMBN-stable 
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group is shown. Original magnification: ×200. Mean±SEM (C-E); **, P＜0.01; *, P＜
0.05. 
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Table S1. Clinical data and immunohistochemical results of AMBN in 37 osteosarcoma 
cases 
 
CDF: continuous disease-free, AWD: alive with disease, NED: no evidence of disease, DOD: dead of disease 
Case No. Age Sex Site Subtype Outcome Follow up (months) 
Lung 
metastasis 
Ameloblastin 
expression 
1 14 M Femur osteoblastic DOD 11 - + 
2 20 M Femur fibroblastic DOD   4 - − 
3 49 M Femur osteoblastic CDF 89 - − 
4 16 M Tibia osteoblastic CDF 82 - + 
5 14 F Tibia osteoblastic DOD   36 + − 
6 13 M Femur osteoblastic DOD  10 + − 
7 13 F Femur osteoblastic DOD  5 - − 
8 19 M Femur teleangiectatic CDF 145 - − 
9 15 F Femur osteoblastic CDF 181 - + 
10 19 F Femur osteoblastic DOD  13 + − 
11 14 M Femur small cell CDF 90 - − 
12 13 M Tibia osteoblastic NED 87 + − 
13 17 F Femur osteoblastic CDF 69 - − 
14 42 M Tibia osteoblastic DOD 43 - − 
15 28 F Tibia osteoblastic CDF 156 - + 
16 24 M Femur osteoblastic DOD 19 - + 
17 12 F Pelvis small cell CDF 147 - + 
18 13 M Femur osteoblastic NED 103 + − 
19 14 F Femur fibroblastic CDF 55 - + 
20 10 M Femur osteoblastic DOD  10 - − 
21 12 F Femur osteoblastic CDF 124 - + 
22 15 M Humerus fibroblastic DOD 37 - − 
23 14 M Tibia fibroblastic CDF 109 - + 
24 69 M Femur parosteal os CDF 73 - − 
25 16 F Humerus telangiectatic  CDF 102 - − 
26 15 M Femur osteoblastic CDF 91 - − 
27 19 F Tibia osteoblastic NED 97 + + 
28 12 M Femur osteoblastic DOD 36 - + 
29 18 F Tibia osteoblastic DOD 26 - − 
30 29 F Femur osteoblastic CDF 55 - − 
31 15 F Femur osteoblastic CDF 51 - + 
32 17 F Tibia fibroblastic CDF 45 - + 
33 15 F Femur osteoblastic CDF 46 - + 
34 88 F Femur fibroblastic CDF 101 - + 
35 8 F Femur osteoblastic DOD - + − 
36 13 F Humerus osteoblastic AWD 61 + − 
37 14 M Femur osteoblastic DOD 5 - + 
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